企業プロフィール
Nektar Therapeutics 株価・ニュース・カタリスト
- ティッカー:
- NKTR
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
72.67 USD (-0.48%)
終値
最終更新: 2026年8月17日
1.98B USD
時価総額
株価変動の要因
As of Aug 17, 2026, NKTR closed down 0.48% at $72.67. No new same-company headline was identified in the current news window.
企業概要
Immune-Regulatory Therapeutics
Nektar Therapeutics develops biologic medicines that selectively modulate immune-cell pathways. Its current portfolio emphasizes regulatory T-cell biology for autoimmune and inflammatory diseases.
Rezpegaldesleukin
Rezpegaldesleukin is an IL-2 pathway agonist designed to expand and activate regulatory T cells without broadly stimulating conventional effector T cells.
Atopic-Dermatitis Development
The Phase 3 ZENITH-AD program is designed to test rezpegaldesleukin in moderate-to-severe atopic dermatitis after Phase 2b results showed responses during treatment and follow-up.
Alopecia-Areata Development
The REZOLVE-AA program evaluates rezpegaldesleukin in severe alopecia areata, including whether treatment effects persist during an off-treatment observation period.
Type 1 Diabetes and Earlier Pipeline
Rezpegaldesleukin is also being studied in a TrialNet-sponsored Phase 2 type 1 diabetes trial. Nektar's earlier portfolio includes TNFR2-directed antibodies such as NKTR-0165.
今後のカタリスト
- Initiation of a registrational Phase 3 study of rezpegaldesleukin in alopecia areata in early 2027.
- Initial Phase 3 ZENITH-AD data for rezpegaldesleukin in atopic dermatitis in mid-2028.
- First planned BLA submission for rezpegaldesleukin in 2029.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。